{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:47:55Z","timestamp":1791985675568,"version":"4.4.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ygyno.2025.04.583","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T19:35:59Z","timestamp":1745523359000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics"],"prefix":"10.1016","volume":"197","author":[{"given":"Kari L.","family":"Ring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke E.","family":"Howitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Euscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Klopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Kolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Glenn","family":"McCluggage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Mirkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Aoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Awujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Ferri-Borgogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"How","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2025.04.583_bb0005","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/00000478-200405000-00006","article-title":"Malignant mesonephric tumors of the female genital tract: a clinicopathologic study of 9 cases","volume":"28","author":"Bagu\u00e9","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.04.583_bb0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00000478-200103000-00013","article-title":"Mesonephric adenocarcinomas of the uterine cervix: a study of 11 cases with Immunohistochemical findings","volume":"25","author":"Silver","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.04.583_bb0015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/PAS.0b013e31824a72c6","article-title":"Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-\u03b2","volume":"36","author":"Kenny","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.04.583_bb0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/PGP.0000000000000088","article-title":"Mesonephric carcinosarcoma involving uterine cervix and vagina: report of 2 cases with immunohistochemical positivity for PAX2, PAX8, and GATA-3","volume":"33","author":"Roma","year":"2014","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"10","key":"10.1016\/j.ygyno.2025.04.583_bb0025","first-page":"7012","article-title":"Mesonephric adenocarcinoma of the uterine corpus","volume":"7","author":"Wu","year":"2025","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.04.583_bb0030","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/PGP.0b013e318166067f","article-title":"Mesonephric adenocarcinoma of the uterine Corpus: a case report and review of the literature","volume":"27","author":"Wani","year":"2008","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.04.583_bb0035","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/ijgc-00009577-200605000-00079","article-title":"Second case of uterine mesonephric adenocarcinoma","volume":"16","author":"Marquette","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2025.04.583_bb0040","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/00000478-200112000-00011","article-title":"Mesonephric adenocarcinoma of the uterine Corpus: CD10 expression as evidence of mesonephric differentiation","volume":"25","author":"Ordi","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.04.583_bb0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1440-1827.1995.tb03461.x","article-title":"Carcinosarcoma of the uterine body of mesonephric origin","volume":"45","author":"Yamamoto","year":"1995","journal-title":"Pathol. Int."},{"issue":"7","key":"10.1016\/j.ygyno.2025.04.583_bb0050","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/his.12895","article-title":"Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas","volume":"68","author":"McFarland","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2025.04.583_bb0055","series-title":"WHO Classification of Tumours: Female Genital Tumours","author":"Board","year":"2020"},{"issue":"5","key":"10.1016\/j.ygyno.2025.04.583_bb0060","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/his.14609","article-title":"Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020)","volume":"80","author":"McCluggage","year":"2022","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.ygyno.2025.04.583_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/diagnostics12020326","article-title":"Mesonephric-like adenocarcinoma of the ovary: clinicopathological and molecular characteristics","volume":"12","author":"Koh","year":"2022","journal-title":"Diagnostics"},{"issue":"6","key":"10.1016\/j.ygyno.2025.04.583_bb0070","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1177\/10668969231213390","article-title":"Mixed mesonephric-like adenocarcinoma, clear cell carcinoma, and endometrioid carcinoma arising from an endometriotic cyst","volume":"32","author":"Nagase","year":"2024","journal-title":"Int. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.04.583_bb0075","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/PGP.0000000000000935","article-title":"Ovarian RASoma with mesonephric-like adenocarcinoma and mixed Mullerian components: a case report with molecular analysis demonstrating multidirectional Mullerian differentiation","volume":"42","author":"Stolnicu","year":"2023","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.04.583_bb0080","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/PGP.0000000000000997","article-title":"Synchronous bilateral ovarian mesonephric-like adenocarcinomas with separate origins from high-grade Mullerian Adenosarcoma and endometriosis: report of a rare case","volume":"43","author":"Zhao","year":"2024","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.04.583_bb0085","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1097\/PAS.0000000000001142","article-title":"A comparison of GATA3, TTF1, CD10, and Calretinin in identifying mesonephric and mesonephric-like carcinomas of the gynecologic tract","volume":"42","author":"Pors","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.04.583_bb0090","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/PAS.0000000000001193","article-title":"A combined morphologic and molecular approach to retrospectively identify KRAS-mutated mesonephric-like adenocarcinomas of the endometrium","volume":"43","author":"Kolin","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.04.583_bb0095","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/PAS.0000000000001401","article-title":"Mesonephric-like carcinoma of the endometrium: a subset of endometrial carcinoma with an aggressive behavior","volume":"44","author":"Euscher","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.04.583_bb0100","doi-asserted-by":"crossref","first-page":"526","DOI":"10.21873\/cgp.20338","article-title":"Mesonephric-like adenocarcinoma of the uterine corpus: comprehensive analyses of clinicopathological, molecular, and prognostic characteristics with retrospective review of 237 endometrial carcinoma cases","volume":"19","author":"Kim","year":"2022","journal-title":"Cancer Genomics Proteomics"},{"issue":"7","key":"10.1016\/j.ygyno.2025.04.583_bb0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/PAS.0000000000001873","article-title":"Mesonephric-like endometrial carcinoma: results from immunohistochemical screening of 300 endometrial carcinomas and Carcinosarcomas for this often overlooked and potentially aggressive entity","volume":"46","author":"Mills","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"issue":"11","key":"10.1016\/j.ygyno.2025.04.583_bb0110","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3390\/diagnostics11112042","article-title":"Mesonephric-like adenocarcinoma of the uterine corpus: comprehensive immunohistochemical analyses using markers for mesonephric, endometrioid and serous tumors","volume":"11","author":"Kim","year":"2021","journal-title":"Diagnostics"},{"issue":"7","key":"10.1016\/j.ygyno.2025.04.583_bb0115","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/his.14892","article-title":"Mesonephric-like adenocarcinoma of the female genital tract: novel observations and detailed molecular characterisation of mixed tumours and mesonephric-like carcinosarcomas","volume":"82","author":"Mirkovic","year":"2023","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.ygyno.2025.04.583_bb0120","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/s41379-021-00799-6","article-title":"Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases","volume":"34","author":"da Silva","year":"2021","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.04.583_bb0125","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/his.14900","article-title":"Commentary: novel observations and detailed molecular characterisation of mixed tumours and mesonephric-like carcinosarcomas by Mirkovic et al. (2023)","volume":"82","author":"Pors","year":"2023","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ygyno.2025.04.583_bb0130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/PAS.0000000000001766","article-title":"Extrauterine mesonephric-like neoplasms: expanding the morphologic Spectrum","volume":"46","author":"Deolet","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.04.583_bb0135","doi-asserted-by":"crossref","first-page":"747","DOI":"10.21873\/cgp.20357","article-title":"Mesonephric-like carcinosarcoma of the uterine corpus: clinicopathological, molecular and prognostic characteristics in comparison with uterine mesonephric-like adenocarcinoma and conventional endometrial carcinosarcoma","volume":"19","author":"Park","year":"2022","journal-title":"Cancer Genomics Proteomics"},{"issue":"4","key":"10.1016\/j.ygyno.2025.04.583_bb0140","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/PAS.0000000000001612","article-title":"Clinicopathologic characteristics of mesonephric adenocarcinomas and mesonephric-like adenocarcinomas in the gynecologic tract: a multi-institutional study","volume":"45","author":"Pors","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.04.583_bb0145","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/his.15308","article-title":"SOX17 expression in mesonephric-like adenocarcinomas and mesonephric remnants\/hyperplasia of the female genital tract: expanding its utility as a M\u00fcllerian biomarker","volume":"85","author":"Zhang","year":"2024","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.ygyno.2025.04.583_bb0150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/his.15312","article-title":"Identifying mesonephric-like adenocarcinoma of the endometrium by combining SOX17 and PAX8 immunohistochemistry","volume":"86","author":"Tahir","year":"2025","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.ygyno.2025.04.583_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.12389","article-title":"Mesonephric-type adenocarcinomas of the ovary: prevalence, diagnostic reproducibility, outcome, and value of PAX2","volume":"10","author":"K\u00f6bel","year":"2024","journal-title":"J. Pathol. Clin. Res."},{"issue":"3","key":"10.1016\/j.ygyno.2025.04.583_bb0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/PGP.0000000000000976","article-title":"Comprehensive immunohistochemical analysis of mesonephric marker expression in low-grade endometrial endometrioid carcinoma","volume":"43","author":"Lee","year":"2024","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.04.583_bb0165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2025.04.583_bb0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2024.01.015","article-title":"Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: a single-center experience with molecular characterization, treatment, and oncologic outcomes","volume":"182","author":"Praiss","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.04.583_bb0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.6217","article-title":"Mesonephric-like adenocarcinoma harbours characteristic copy number variations and a distinct DNA methylation signature closely related to mesonephric adenocarcinoma of the cervix","volume":"262","author":"Kommoss","year":"2024","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.04.583_bb0180","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PAS.0000000000000991","article-title":"Clinicopathologic and molecular characteristics of mesonephric adenocarcinoma arising from the uterine body","volume":"43","author":"Na","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.04.583_bb0185","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.21873\/anticanres.16332","article-title":"Mesonephric-like adenocarcinoma of the uterine corpus: comparison between mismatch repair protein immunostaining and microsatellite instability testing","volume":"43","author":"Kim","year":"2023","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2025.04.583_bb0190","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2025.01.006","article-title":"Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: ancillary analysis of GOG-0258","volume":"193","author":"Clements","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2025.04.583_bb0195","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus Pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.583_bb0200","first-page":"37","article-title":"Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma","author":"Shen","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"issue":"9","key":"10.1016\/j.ygyno.2025.04.583_bb0205","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.3390\/curroncol31090378","article-title":"Ovarian mesonephric-like adenocarcinoma: its prevalence in a Japanese high-volume Cancer center and a literature review on therapeutic targets","volume":"31","author":"Ogawa","year":"2024","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.04.583_bb0210","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/PAS.0000000000002039","article-title":"Extrauterine mesonephric-like carcinoma","volume":"47","author":"Euscher","year":"2023","journal-title":"Am. J. Surg. Pathol."},{"issue":"13","key":"10.1016\/j.ygyno.2025.04.583_bb0215","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/djq149","article-title":"Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial","volume":"102","author":"Trimbos","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2025.04.583_bb0220","doi-asserted-by":"crossref","first-page":"S728","DOI":"10.1016\/j.annonc.2021.08.1168","article-title":"725MO phase I study of the combination of the dual RAF\/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: results of efficacy in low grade serous ovarian cancer","volume":"32","author":"Banerjee","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.583_bb0225","doi-asserted-by":"crossref","first-page":"S591","DOI":"10.1016\/j.annonc.2021.08.1046","article-title":"524P a phase I, open-label, dose-escalation trial of BI 1701963 in patients (pts) with KRAS mutated solid tumours: a snapshot analysis","volume":"32","author":"Johnson","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.04.583_bb0230","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"issue":"10427","key":"10.1016\/j.ygyno.2025.04.583_bb0235","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:07:54Z","timestamp":1791983274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825008091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":47,"alternative-id":["S0090825825008091"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.04.583","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.04.583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}